A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants With Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection
Latest Information Update: 03 Mar 2025
At a glance
- Drugs Nivolumab (Primary) ; Hyaluronidase; Nivolumab
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational
- Acronyms CheckMate-6GE
- Sponsors Bristol-Myers Squibb
- 29 Feb 2024 Status changed from active, no longer recruiting to completed.
- 23 Feb 2024 This study has been Completed in Belgium, According to European Clinical Trials Database record.
- 13 Dec 2023 Planned End Date changed from 28 Feb 2024 to 12 Feb 2024.